Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Product Categories
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

M-3258 is an inhibitor of the immunoproteasome subunit large multifunctional peptidase 7 (LMP7; IC50 = 4.1 nM).1 It is selective for LMP7 over the 20S proteasomal catalytic subunits β1, -β2, and -β5 (IC50s = >10,000, 2,519, and >10,000 nM, respectively), as well as LMP2 and proteosome subunit beta type 10 (PSMB10; IC50s = >10,000 nM for both). It increases ubiquitinated protein levels (EC50 = 1,980 nM) and induces apoptosis in MM.1S multiple myeloma cells (EC50 = 420 nM). M-3258 (10 mg/kg per day) reduces tumor volume in U266B1, OPM-2, and RPMI-8226 mouse xenograft models of multiple myeloma.
WARNING This product is not for human or veterinary use.
1. M3258 is a selective inhibitor of the immunoproteasome subunit LMP7 (β5i) delivering efficacy in multiple myeloma models. Mol. Cancer Ther. 20(8), 1378-1387 (2021).